Axol Bioscience has made significant strides in the biotechnology landscape by acquiring the ophthalmology division of Newcells Biotech. This strategic move enhances Axol’s existing portfolio of induced pluripotent stem cell (iPSC)-derived retinal models and strengthens its role in preclinical research focused on eye diseases.
This acquisition, announced on February 18, 2026, in Cambridge and Newcastle, brings with it a specialized team, advanced facilities, and a wealth of intellectual property centered on proprietary iPSC-derived products. These offerings cater to biopharmaceutical and biotechnology companies, as well as contract research organizations (CROs) across Europe and the United States. The platforms developed over the past decade include sophisticated retinal organoids and 2D retinal pigment epithelium models, both vital for supporting preclinical and translational drug development.
Strategic Expansion in Ophthalmology
Axol’s acquisition of Newcells is a continuation of its strategic expansion into the ophthalmology sector, which began with the purchase of Phenocell in October 2024. This focus comes at a time when investments in research concerning conditions like age-related macular degeneration, glaucoma, and various rare diseases are on the rise.
By integrating Newcells’ ophthalmology business, Axol reinforces its standing as a premier independent provider of iPSC-derived in vitro models tailored for ophthalmology drug discovery. This acquisition not only diversifies Axol’s offerings but also enhances its capabilities in gene therapy development and retinal safety assessments.
Financial Backing for Growth
This acquisition follows a recent financing round in which Axol secured $2.8 million, led by BroadOak Capital Partners. This funding aims to bolster Axol’s commercial operations in the U.S., alongside enhancing product development and manufacturing capabilities. The financial support lays a strong foundation for future growth, allowing Axol to expand its reach and impact in the biotech sector.
Liam Taylor, CEO of Axol Bioscience, articulated the company’s vision: “With our recent financing and robust revenue growth, we’re executing a strategy to scale Axol internationally while enhancing our scientific capabilities. The acquisition of Newcells’ retinal organoid business is our third in five years, significantly strengthening our ophthalmology offerings and positioning us as leaders in the field.”
Integrating Advanced Technologies
Florian Regent, Axol’s Head of Ophthalmology, highlighted the sophistication of Newcells’ retinal organoid platform. He noted that these predictive, human-relevant iPSC-derived retinal models have gained recognition throughout the industry for their scalability and effectiveness.
By merging Newcells’ capabilities with its own, Axol aims to provide a more extensive and physiologically relevant toolkit for researchers. This integration is critical as drug developers increasingly seek predictive human models that can mitigate risks early in the development process. The acquisition thus positions Axol at the forefront of ophthalmology drug discovery and safety testing.
Future Directions in Biotech
The acquisition of Newcells’ ophthalmology unit is a testament to Axol’s commitment to innovation in the biotech sector. As the company continues to grow and adapt, its focus on developing cutting-edge solutions for eye disease will likely yield promising advancements in treatment and drug discovery.
Looking ahead, Axol is set to play a pivotal role in shaping the future of ophthalmology research. By building on its strengths and expanding its capabilities, the company is well-positioned to meet the evolving needs of the biopharmaceutical industry.
Key Takeaways
- Axol Bioscience has acquired Newcells Biotech’s ophthalmology division, enhancing its portfolio of iPSC-derived retinal models.
-
The acquisition strengthens Axol’s position as a leader in ophthalmology drug discovery and expands its service offerings to biopharma and CRO clients.
-
Financial backing from BroadOak Capital Partners supports Axol’s growth and expansion plans, particularly in the U.S. market.
-
The integration of Newcells’ sophisticated retinal organoid platform allows for more predictive and relevant research tools in drug development.
In conclusion, Axol Bioscience’s acquisition of Newcells not only diversifies its product offerings but also underscores its commitment to advancing research in ophthalmology. As the landscape of biopharmaceuticals continues to evolve, this strategic move positions Axol to make significant contributions to the field, paving the way for future innovations in eye disease treatment.
Read more → pharmatimes.com